Volume | 324,978 |
|
|||||
News | - | ||||||
Day High | 36.74 | Low High |
|||||
Day Low | 35.65 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Celldex Therapeutics Inc | CLDX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
36.31 | 35.65 | 36.74 | 36.30 | 36.26 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
6,959 | 324,978 | $ 36.39 | $ 11,826,693 | - | 22.11 - 53.18 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:31:55 | 1 | $ 35.45 | USD |
Celldex Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.03B | 55.90M | - | 6.88M | -141.43M | -2.53 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Celldex Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CLDX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 38.24 | 39.67 | 35.65 | 37.40 | 599,477 | -1.94 | -5.07% |
1 Month | 41.84 | 41.84 | 35.65 | 39.32 | 643,144 | -5.54 | -13.24% |
3 Months | 35.25 | 53.18 | 34.65 | 43.36 | 960,588 | 1.05 | 2.98% |
6 Months | 23.72 | 53.18 | 22.11 | 37.92 | 889,118 | 12.58 | 53.04% |
1 Year | 33.89 | 53.18 | 22.11 | 35.65 | 674,045 | 2.41 | 7.11% |
3 Years | 27.99 | 57.20 | 19.85 | 35.72 | 626,984 | 8.31 | 29.69% |
5 Years | 3.64 | 57.20 | 1.50 | 24.53 | 681,660 | 32.66 | 897.25% |
Celldex Therapeutics Description
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. |